Nerviano and Servier Announce Collaboration and License for Novel Anticancer Drug

Nerviano Medical Sciences and Servier have announced that they have agreed a collaboration and license agreement for a novel anticancer drug.

The deal will see the further development and commercialisation of the first-in-class Nerviano compounds inhibiting the protein kinase TTK/MPS1, which is a key regulator of mitosis and aberrantly overexpressed in a wide range of tumours and represents a promising target in oncology.

An upfront fee of £6.9 million will be paid, with the potential for up to £86.7 million in option fees based on clinical and regulatory milestones, alongside royalties for the sale of the products.

Professor Alberto Sciume, president of Nerviano Medical Sciences, said: "We are very pleased to enter into this partnership with Servier as both companies share the common goal to develop innovative drugs in oncology.

"I am confident that Nerviano's expertise in drug discovery and development will lead to new therapies that will ultimately deliver hope and innovative therapies to cancer patients."